Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Total Debt

Short-term and long-term borrowings combined.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Total Debt · Q4 FY2025 · quarter ended Dec 2025

Total debt rises 18.7% from a year ago

Total debt stood at CN¥1.98B at the end of Q4 FY2025, up 18.7% from a year earlier. Over 3 fiscal years it compounded at +3.4% a year.

Context

  • Total debt amounted to 49.9% of total assets at the end of Q4 FY2025, down 13.8 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +18.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥1.98B— QoQ
Last fiscal yearDec 2025
CN¥1.98B+18.7% YoY
Year agoDec 2024
CN¥1.67B+18.7% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.7%——
1 year+18.7%——
3-year CAGR+3.4%——
5-year CAGR——
10-year CAGR——

Total Debt history

CNY · from the balance sheet

Latest · FY2025
1.98B CNY
Year-over-year change
+18.7%
4-year CAGR
+16.3%

Total Debt vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +18.7% is the 5th highest of 11, against a peer median of +13.5%.
  • Total debt amounts to 49.9% of total assets for AAPG, versus a peer median of 11.6%.
AAPG Competitors
Total Debt for AAPG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$3.73B USD+91265.7%-7.6%1.7%
AAPGAscentage Pharma Group InternationalDec 2025CN¥1.98B CNY+18.7%+3.4%49.9%
ZLABZai Lab LimitedJun 2026$254.58M USD+33.0%+122.4%23.7%
NUVBNuvation Bio Inc.Jun 2026$252.14M USD+336.5%+33.5%33.9%
VSTMVerastem, Inc.Mar 2026$85.48M USD+11.3%+41.6%37.5%
NRIXNurix Therapeutics, Inc.Aug 2026$65.33M USD+15.7%+67.0%5.5%
CCCCC4 Therapeutics, Inc.Mar 2026$58.45M USD-9.2%-11.7%17.8%
TNGXTango Therapeutics, Inc.Sep 2026$31.18M USD-10.3%-6.5%3.0%
IDYAIDEAYA Biosciences, Inc.Mar 2026$28.6M USD+10.1%+100.1%2.8%
ANLAdlai Nortye Ltd.Dec 2025$26.38M USD-3.1%+59.1%76.6%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$419K USD+203.6%-53.5%0.1%
Peer median (excluding AAPG) —+13.5%+37.6%11.6%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents1.71B1.48B1.07B1.24B2.47B
Short-term Investments00000
Net Receivables54.13M61.49M163.54M99.07M253.1M
Inventory3.93M9.45M16.17M6.6M28.64M
Other Current Assets59.26M16.6M24.54M24.63M192.65M
Total Current Assets1.89B1.64B1.34B1.47B2.95B
Property, Plant & Equipment (Net)854.3M650.03M957.23M905.86M829.59M
Goodwill24.69M24.69M24.69M24.69M24.71M
Intangible Assets60.41M84.3M85.45M76M65.98M
Long-term Investments27.85M18.53M18.95M33.86M37.05M
Tax Assets51.65M54.29M59.84M44.24M31.98M
Other Non-current Assets35.88M361.93M10.05M59M30.74M
Total Non-current Assets1.05B1.19B1.16B1.14B1.02B
Total Assets2.94B2.83B2.5B2.62B3.97B
Account Payables70.86M95.56M72.45M91.97M106.81M
Short-term Debt39.8M510.31M606.65M769.62M1.22B
Tax Payables3.28M7.18M8.39M9.63M0
Deferred Revenue024.35M38.41M54.09M37.51M
Other Current Liabilities58.73M2.82M00276.84M
Total Current Liabilities361.11M881.15M934.17M1.17B1.64B
Long-term Debt1.03B1.27B1.17B868.64M742.8M
Deferred Tax Liabilities13.75M12.15M10.55M5.37M0
Deferred Revenue (Non-current)243.28M218.63M287.55M275.96M216.86M
Other Non-current Liabilities52.34M35.33M18.3M6.27M12.04M
Total Non-current Liabilities1.34B1.54B1.5B1.18B986.62M
Total Liabilities1.71B2.42B2.43B2.34B2.63B
Common Stock178K180K197K214K256.16K
Retained Earnings(3.56B)(4.44B)(5.37B)(5.77B)0
Accumulated OCI(550.95M)(518.51M)(504.46M)(510.59M)1.33B
Other Stockholders Equity00000
Minority Interest0010.22M9.97M9.76M
Total Equity1.23B408.66M70.63M274.16M1.34B
Total Debt1.08B1.79B1.8B1.67B1.98B
Net Debt(622.6M)317.09M726.3M431.92M(490.68M)

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.